deliv good beat revenu growth
organ ahead street estim organ normal ep
also consensu expect revenu guidanc
ep street
estim respect anticip euroimmun help acceler perkin
diagnost busi rais estim price target
base ep ep
happen report robust organ revenu growth
well ahead street estim organ growth
euroimmun close decemb ad report revenu
discoveri analyt system da grew organ report
ahead street respect diagnost grew
organ lower organ basi street estim
gross margin decreas bpt street oper
expens yield adjust oper margin street product
mix reason lower expect adjust oper margin top line
beat led ep upsid
pipeline/euroimmun updat manag began cross train
exist perkin rep euroimmun team highlight potenti synergi
indian tulip team well although sound long-term manag
remain bullish pipelin vanadi system decentr non-invas prenat
test initi target trisomi well sex-chromosom system
target ce mark data releas around launch manag
dial revenu target
guidance/model updat manag guid revenu
consist core growth
euroimmun
euroimmun contribut manag guid bpt gross
margin expans somewhat off-set higher read euroimmun
oper expens corpor tax reform net neg euroimmun
still add ep yield increas
forward estim reflect strong underli da busi
stock continu believ share grind higher
beat rais quarter like one increas forward estim
also shift valuat methodolog yield target
competit emerg disrupt technolog execut new product launch
foreign currenc
develop manufactur sell product environment market
forma ep
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
million
good sold
provis incom tax
good sold
research develop
compani report piper jaffray co up-to-d compani disclosur inform pleas visit http //www piperjaffray com/researchdisclosur
